New targets for Ph+ leukaemia therapy

Best Practice and Research: Clinical Haematology

Volumn 22, Issue 3, 2009, Pages 445-454

  Martinelli, Giovanni ^a   Iacobucci, Ilaria ^a   Papayannidis, Cristina ^a   Soverini, Simona ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Aurora kinases; BCR ABL; GEP; GSK3 splicing; new targets; resistance; Smo inhibitors; TKI

Indexed keywords

2 [[3 [4 [5 [2 (3 FLUOROANILINO) 2 OXOETHYL] 1H PYRAZOL 3 YLAMINO] 7 QUINAZOLINYLOXY]PROPYL](ETHYL)AMINO]ETHYL DIHYDROGEN PHOSPHATE; 4 (3 DIMETHYLAMINO 1 PYRROLIDINYLMETHYL) 3 TRIFLUOROMETHYL N [4 METHYL 3 [[4 (5 PYRIMIDINYL) 2 PYRIMIDINYL]AMINO]PHENYL]BENZAMIDE; 6 (2,6 DICHLOROPHENYL) 2 (4 FLUORO 3 METHYLANILINO) 8 METHYL 8H PYRIDO[2,3 D]PYRIMIDIN 7 ONE; 6 (2,6 DICHLOROPHENYL) 2 [3 (HYDROXYMETHYL)ANILINO] 8 METHYLPYRIDO[2,3 D]PYRIMIDIN 7(8H) ONE; 6 (2,6 DICHLOROPHENYL) 8 METHYL 2 (3 METHYLTHIOANILINO) 8H PYRIDO[2,3 D]PYRIMIDIN 7 ONE; 7 HYDROXYSTAUROSPORINE; [4 [2 CYCLOPENTYL 9 (3 HYDROXYPHENETHYL)PURIN 6 YLAMINO]PHENYL]DIMETHYLPHOSPHINE OXIDE; AS 703569; AURORA KINASE INHIBITOR; BCR ABL PROTEIN; BOSUTINIB; CYCLOPAMINE; CYCLOPROPANECARBOXYLIC ACID [4 [4 (4 METHYL 1 PIPERAZINYL) 6 (5 METHYL 2H PYRAZOL 3 YLAMINO) 2 PYRIMIDINYLTHIO]PHENYL]AMIDE; DANUSERTIB; DASATINIB; DCC 2036; EVEROLIMUS; IMATINIB; KW 2449; N (5 CHLORO 1,3 BENZODIOXOL 4 YL) 7 [2 (4 METHYL 1 PIPERAZINYL)ETHOXY] 5 (TETRAHYDRO 2H PYRAN 4 YLOXY) 4 QUINAZOLINAMINE; NILOTINIB; PD 173855; PROTEIN TYROSINE KINASE INHIBITOR; SGX 70430; SORAFENIB; TEMSIROLIMUS; UNCLASSIFIED DRUG; XL 228;

ACUTE LYMPHOBLASTIC LEUKEMIA; BLAST CELL CRISIS; BONE MARROW SUPPRESSION; CANCER RESISTANCE; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; DIARRHEA; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TARGETING; GENE EXPRESSION PROFILING; HETEROZYGOSITY LOSS; HUMAN; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; NAUSEA; NONHUMAN; PERIPHERAL EDEMA; PHILADELPHIA 1 CHROMOSOME; PLEURA EFFUSION; POINT MUTATION; PRIORITY JOURNAL; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; SOLID TUMOR;

DRUG DELIVERY SYSTEMS; DRUG DISCOVERY; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 71849095196     PISSN: 15216926     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.beha.2009.08.002     Document Type: Review

References (60)

1. Nowell P.C., and Hungerford D.A. Chromosome studies on normal and leukemic human leukocytes. J Natl Cancer Inst 25 (1960) 85-109
2. Wong S., and Witte O.N. The BCR-ABL story: bench to bedside and back. Annu Rev Immunol 22 (2004) 247-306
3. Druker B., Guilhot F., O'Brien S.G., et al. Long-term benefits of imatinib (IM) for patients newly diagnosed with chronic myelogenous leukemia in chronic phase (CML-CP): the 5-year update from the IRIS study. J Clin Oncol 24 18S (2006) 6506 2006 ASCO Annual Meeting Proceedings
4. Fidanza V., Melotti P., Yano T., et al. Double knockout of the ALL-1 gene blocks hematopoietic differentiation in vitro. Cancer Res 56 6 (1996) 1179-1183
5. Arico M., Valsecchi M.G., Camitta B., et al. Outcome of treatment in children with Philadelphia chromosome-positive acute lymphoblastic leukemia. N Engl J Med 342 14 (2000) 998-1006
6. Gleissner B., Gokbuget N., Bartram C.R., et al. Leading prognostic relevance of the BCR-ABL translocation in adult acute B-lineage lymphoblastic leukemia: a prospective study of the German Multicenter Trial Group and confirmed polymerase chain reaction analysis. Blood 99 5 (2002) 1536-1543
7. Crossman L.C., Mori M., Hsieh Y.C., et al. In chronic myeloid leukemia white cells from cytogenetic responders and non-responders to imatinib have very similar gene expression signatures. Haematologica 90 4 (2005) 459-464
8. Baccarani M., Saglio G., Goldman J., et al. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 108 6 (2006) 1809-1820
9. Iacobucci I., Ottaviani E., Astolfi A., et al. High-resolution genomic profiling of Ph-positive acute lymphoblastic leukaemia (ALL) identified recurrent copy number anomalies in genes regulating the cell cycle and the B-cell differentiation. Haematologica 93 (2008) 1084
10. Cerutti A., Zan H., Kim E.C., et al. Ongoing in vivo immunoglobulin class switch DNA recombination in chronic lymphocytic leukemia B cells. J Immunol 169 11 (2002) 6594-6603
11. Kantarjian H., Giles F., Wunderle L., et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med 354 24 (2006) 2542-2551
12. Talpaz M., Shah N.P., Kantarjian H., et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med 354 24 (2006) 2531-2541
13. Jovanovic J.V., Score J., Waghorn K., et al. Low-dose imatinib mesylate leads to rapid induction of major molecular responses and achievement of complete molecular remission in FIP1L1-PDGFRA-positive chronic eosinophilic leukemia. Blood 109 11 (2007) 4635-4640
14. Bruemmendorf T.H., FC, Kim D., et al. Bosutinib is safe and active in patients (pts) with chronic phase (CP) chronic myeloid leukemia (CML) with resistance or intolerance to imatinib and other tyrosine kinase inhibitors. J Clin Oncol 26 (2008) [May 20 Suppl.]
15. Golemovic M., Verstovsek S., Giles F., et al. AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, has in vitro activity against imatinib-resistant chronic myeloid leukemia. Clin Cancer Res 11 13 (2005) 4941-4947
16. O'Hare T., Walters D.K., Stoffregen E.P., et al. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res 65 11 (2005) 4500-4505
17. Giles F.J., Cortes J., Jones D., et al. MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation. Blood 109 2 (2007) 500-502
18. Foa R., VM, Vitale A., et al. Dasatinib as front-line monotherapy for the induction treatment of adult and elderly Ph? Acute lymphoblastic leukemia (ALL) patients: interim analysis of the GIMEMA prospective study LAL1205. Blood (2007) [110:7a. abstract]
19. Puttini M., Coluccia A.M., Boschelli F., et al. In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cells. Cancer Res 66 23 (2006) 11314-11322
20. Tafuri A., Gregorj C., Petrucci M.T., et al. MDR1 protein expression is an independent predictor of complete remission in newly diagnosed adult acute lymphoblastic leukemia. Blood 100 3 (2002) 974-981
21. Corbin A.S., LRP, Stoffregen E.P., et al. Several Bcr-Abl kinase domain mutants associated with imatinib mesylate resistance remain sensitive to imatinib. Blood 101 (2003) 4611-4614
22. Carter T.A., Wodicka L.M., Shah N.P., et al. Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases. Proc Natl Acad Sci U S A 102 31 (2005) 11011-11016
23. Young M.A., Shah N.P., Chao L.H., et al. Structure of the kinase domain of an imatinib-resistant Abl mutant in complex with the Aurora kinase inhibitor VX-680. Cancer Res 66 2 (2006) 1007-1014
24. O'Hare T., Pollock R., Stoffregen E.P., et al. Inhibition of wild-type and mutant Bcr-Abl by AP23464, a potent ATP-based oncogenic protein kinase inhibitor: implications for CML. Blood 104 8 (2004) 2532-2539
25. Azam M., Nardi V., Shakespeare W.C., et al. Activity of dual SRC-ABL inhibitors highlights the role of BCR/ABL kinase dynamics in drug resistance. Proc Natl Acad Sci U S A 103 24 (2006) 9244-9249
26. Kimura S., Ashihara E., and Maekawa T. New tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia. Curr Pharm Biotechnol 7 5 (2006) 371-379
27. Naito H., Kimura S., Nakaya Y., et al. In vivo antiproliferative effect of NS-187, a dual Bcr-Abl/Lyn tyrosine kinase inhibitor, on leukemic cells harbouring Abl kinase domain mutations. Leuk Res 30 11 (2006) 1443-1446
28. Nagar B., Bornmann W.G., Pellicena P., et al. Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571). Cancer Res 62 15 (2002) 4236-4243
29. Dorsey J.F., Jove R., Kraker A.J., et al. The pyrido[2,3-d]pyrimidine derivative PD180970 inhibits p210Bcr-Abl tyrosine kinase and induces apoptosis of K562 leukemic cells. Cancer Res 60 12 (2000) 3127-3131
30. Huron D.R., Gorre M.E., Kraker A.J., et al. A novel pyridopyrimidine inhibitor of abl kinase is a picomolar inhibitor of Bcr-abl-driven K562 cells and is effective against STI571-resistant Bcr-abl mutants. Clin Cancer Res 9 4 (2003) 1267-1273
31. Gumireddy K., Baker S.J., Cosenza S.C., et al. A non-ATP-competitive inhibitor of BCR-ABL overrides imatinib resistance. Proc Natl Acad Sci U S A 102 6 (2005) 1992-1997
32. Katayama H., Brinkley W.R., and Sen S. The Aurora kinases: role in cell transformation and tumorigenesis. Cancer Metastasis Rev 22 4 (2003) 451-464
33. Hata T., Furukawa T., Sunamura M., et al. RNA interference targeting aurora kinase a suppresses tumor growth and enhances the taxane chemosensitivity in human pancreatic cancer cells. Cancer Res 65 7 (2005) 2899-2905
34. Katayama H., Sasai K., Kawai H., et al. Phosphorylation by aurora kinase A induces Mdm2-mediated destabilization and inhibition of p53. Nat Genet 36 1 (2004) 55-62
35. Hu H.M., Chuang C.K., Lee M.J., et al. Genomic organization, expression, and chromosome localization of a third aurora-related kinase gene, Aie1. DNA Cell Biol 19 11 (2000) 679-688
36. Kufer T.A., Nigg E.A., and Sillje H.H. Regulation of Aurora-A kinase on the mitotic spindle. Chromosoma 112 4 (2003) 159-163
37. Rojanala S., Han H., Munoz R.M., et al. The mitotic serine threonine kinase, Aurora-2, is a potential target for drug development in human pancreatic cancer. Mol Cancer Ther 3 4 (2004) 451-457
38. Li D., Zhu J., Firozi P.F., et al. Overexpression of oncogenic STK15/BTAK/Aurora A kinase in human pancreatic cancer. Clin Cancer Res 9 3 (2003) 991-997
39. Jeng Y.M., Peng S.Y., Lin C.Y., et al. Overexpression and amplification of Aurora-A in hepatocellular carcinoma. Clin Cancer Res 10 6 (2004) 2065-2071
40. Hoque A., Carter J., Xia W., et al. Loss of aurora A/STK15/BTAK overexpression correlates with transition of in situ to invasive ductal carcinoma of the breast. Cancer Epidemiol Biomarkers Prev 12 12 (2003) 1518-1522
41. Moreno-Bueno G., Sanchez-Estevez C., Cassia R., et al. Differential gene expression profile in endometrioid and nonendometrioid endometrial carcinoma: STK15 is frequently overexpressed and amplified in nonendometrioid carcinomas. Cancer Res 63 18 (2003) 5697-5702
42. Gritsko T.M., Coppola D., Paciga J.E., et al. Activation and overexpression of centrosome kinase BTAK/Aurora-A in human ovarian cancer. Clin Cancer Res 9 4 (2003) 1420-1426
43. Reichardt W., Jung V., Brunner C., et al. The putative serine/threonine kinase gene STK15 on chromosome 20q13.2 is amplified in human gliomas. Oncol Rep 10 5 (2003) 1275-1279
44. Hamada M., Yakushijin Y., Ohtsuka M., et al. Aurora2/BTAK/STK15 is involved in cell cycle checkpoint and cell survival of aggressive non-Hodgkin's lymphoma. Br J Haematol 121 3 (2003) 439-447
45. Dewar H., Tanaka K., Nasmyth K., et al. Tension between two kinetochores suffices for their bi-orientation on the mitotic spindle. Nature 428 6978 (2004) 93-97
46. Murata-Hori M., and Wang Y.L. The kinase activity of aurora B is required for kinetochore-microtubule interactions during mitosis. Curr Biol 12 11 (2002) 894-899
47. Araki K., Nozaki K., Ueba T., et al. High expression of Aurora-B/Aurora and Ipll-like midbody-associated protein (AIM-1) in astrocytomas. J Neurooncol 67 1-2 (2004) 53-64
48. Sorrentino R., Libertini S., Pallante P.L., et al. Aurora B overexpression associates with the thyroid carcinoma undifferentiated phenotype and is required for thyroid carcinoma cell proliferation. J Clin Endocrinol Metab 90 2 (2005) 928-935
49. Sasai K., Katayama H., Stenoien D.L., et al. Aurora-C kinase is a novel chromosomal passenger protein that can complement Aurora-B kinase function in mitotic cells. Cell Motil Cytoskeleton 59 4 (2004) 249-263
50. Kimura M., Matsuda Y., Yoshioka T., et al. Cell cycle-dependent expression and centrosome localization of a third human aurora/Ipl1-related protein kinase, AIK3. J Biol Chem 274 11 (1999) 7334-7340
51. Papayannidis II C., Soverini S., Paolini S., et al. Innovative phase I-II study of concomitant and consecutive treatment with Dasatinib and MK-0457 in refractory Ph+ CML and ALL patients AACR. Abstract meetings (2009)
52. + ALL patients resistant to imatinib. Haematologica (2007) SIE 2007 Abstract Book
53. Mullighan C.G., Miller C.B., Radtke I., et al. BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros. Nature 453 7191 (2008) 110-114
54. Iacobucci I., Lonetti A., Messa F., et al. Expression of spliced oncogenic Ikaros isoforms in Philadelphia-positive acute lymphoblastic leukemia patients treated with tyrosine kinase inhibitors: implications for a new mechanism of resistance. Blood (2008)
55. Mullighan C.G., Williams R.T., Downing J.R., et al. Failure of CDKN2A/B (INK4A/B-ARF)-mediated tumor suppression and resistance to targeted therapy in acute lymphoblastic leukemia induced by BCR-ABL. Genes Dev 22 11 (2008) 1411-1415
56. Abrahamsson A.E., Geron I., Gotlib J., et al. Glycogen synthase kinase 3beta missplicing contributes to leukemia stem cell generation. Proc Natl Acad Sci U S A 106 10 (2009) 3925-3929
57. Iacobucci I., Storlazzi C.T., Cilloni D., et al. Identification and molecular characterisation of recurrent genomic deletions on 7p12 in the IKZF1 gene in a large cohort of BCR-ABL1-positive acute lymphoblastic leukaemia patients: on behalf of GIMEMA AL WP. Blood Jul (2009) Epub ahed of print
58. Kwok J.B., Hallupp M., Loy C.T., et al. GSK3B polymorphisms alter transcription and splicing in Parkinson's disease. Ann Neurol 58 6 (2005) 829-839
59. Zhao C., Chen A., Jamieson C.H., et al. Hedgehog signalling is essential for maintenance of cancer stem cells in myeloid leukaemia. Nature 458 7239 (2009) 776-779
60. Williams J.A. Hedgehog signaling pathway as a target for therapeutic intervention in basal cell carcinoma. Drug News Perspect 16 10 (2003) 657-662